R&D Highlights
Facts
- Since 2002, we have delivered nine important new products to patients in need, including two biologic medicines.
- In 2009, we increased the number of compounds in Exploratory and Full Development by nearly 40 percent.
- Biologics account for about one-third of our compounds in development.
- We invested $3.6 billion in research & development in 2009.
Product Approvals Since 2002
- ABILIFY® (aripiprazole), November 2002, new molecular entity
- REYATAZ® (atazanavir sulfate), June 2003, new molecular entity
- ERBITUX® (cetuximab), February 2004, new molecular entity
- BARACLUDE® (entecavir), March 2005, new molecular entity
- ORENCIA® (abatacept), December 2005, new molecular entity
- SPRYCEL® (dasatinib), June 2006, new molecular entity
- ATRIPLA® (efavirenz / emtricitabine /tenofovir disoproxil fumarate), July 2006
- IXEMPRA™ (ixabepilone), October 2007, new molecular entity
- ONGLYZA™ (saxagliptin), July 2009, new molecular entity
January 2010
Bristol-Myers Squibb and Allergan, Inc. announced a global agreement for the development and commercialization of an oral medication for the treatment of neuropathic pain.
November 2009
We entered a global agreement with Alder Biopharmaceuticals for the development and commercialization of ALD 518, a novel biologic under development for the treatment of rheumatoid arthritis.
August 2009
Bristol-Myers Squibb acquired Medarex Inc., a biotech company and a partner since 2005. The acquisition significantly expanded Bristol-Myers Squibb's oncology and immunology pipeline, positioned the company for long-term leadership in biologics and allowed it to gain full rights for ipilimumab, an investigational compound for metastatic melanoma.
March 2009
We entered into a global collaboration with Nissan Chemical Industries, Ltd. and Teijin Pharma Limited for the development and commercialization of NTC-801, a selective inhibitor of the acetylcholine-activated potassium ion channel (IKACh) for the maintenance of normal sinus rhythm in patients with atrial fibrillation.
January 2009
We entered into a global collaboration with ZymoGenetics for PEG-Interferon lambda, a novel type three interferon in development for hepatitis C.
December 2008
We entered global collaboration with Exelixis covering two novel cancer compounds and their related development programs, XL184, a small molecule inhibitor of MET, VEGFR2 and RET, and XL 281, a small molecule inhibitor of RAF kinase.
August 2008
We entered into a licensing agreement for global development and commercialization of PDL BioPharma’s anti-CS1 antibody, elotuzumab, for multiple myeloma.
June 2008
We acquired Kosan Biosciences, a cancer therapeutics company developing compounds in two classes of anticancer agents: novel Hsp90 inhibitors, for multiple myeloma and epothilones.
May 2008
We entered an exclusive agreement with KAI Pharmaceuticals for global development and commercialization of KAI-9803, a first-in-class inhibitor of the delta protein kinase C pathway for cardiac reperfusion therapy.
October 2007
We acquired Adnexus Therapeutics, a biotech company with a proprietary and novel class of biologics called Adnectins™ and a proprietary protein engineering system called PROfusion.™